(NX) Quanex Building Products - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7476191041
NX: Windows, Doors, Insulation, Cabinets, Solar, Fencing, Decking
Quanex Building Products Corporation (NYSE:NX) is a key player in the fenestration industry, specializing in components for windows, doors, and cabinet systems. With operations spanning North America, Europe, and Asia, the company serves a diverse range of markets, from residential construction to commercial building projects. Its product portfolio includes essential components like insulating glass spacers, vinyl profiles, and precision-formed metal products, all critical for energy efficiency and structural integrity in modern buildings.
Quanex operates through three primary segments: North American Fenestration, European Fenestration, and North American Cabinet Components. This segmentation allows the company to cater to regional market demands while maintaining operational efficiency. Beyond its core fenestration products, Quanex also manufactures non-fenestration components such as solar panel sealants, vinyl decking, and water retention barriers, diversifying its revenue streams and reducing dependence on a single market.
The company’s financial health is reflected in its market capitalization of $1.007 billion, with a trailing P/E ratio of 23.71 and a forward P/E of 9.77, indicating expectations of future earnings growth. The price-to-book ratio of 1.03 suggests the market values the company’s assets at a modest premium, while the price-to-sales ratio of 0.93 points to a reasonable valuation relative to its revenues.
Quanex’s customer base includes original equipment manufacturers (OEMs) in the building products industry, with sales facilitated through a mix of direct sales forces, distributors, and independent agents. This multi-channel approach ensures broad market reach and customer accessibility. Founded in 1927 and headquartered in Houston, Texas, Quanex has established itself as a
Additional Sources for NX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NX Stock Overview
Market Cap in USD | 979m |
Sector | Industrials |
Industry | Building Products & Equipment |
GiC Sub-Industry | Building Products |
IPO / Inception | 1987-12-30 |
NX Stock Ratings
Growth 5y | 11.2% |
Fundamental | -16.9% |
Dividend | 38.0% |
Rel. Strength Industry | -40.3 |
Analysts | 5/5 |
Fair Price Momentum | 15.94 USD |
Fair Price DCF | 23.77 USD |
NX Dividends
Dividend Yield 12m | 1.28% |
Yield on Cost 5y | 1.80% |
Annual Growth 5y | 0.00% |
Payout Consistency | 95.1% |
NX Growth Ratios
Growth Correlation 3m | -92.9% |
Growth Correlation 12m | -79.8% |
Growth Correlation 5y | 73.1% |
CAGR 5y | 2.77% |
CAGR/Max DD 5y | 0.05 |
Sharpe Ratio 12m | -0.97 |
Alpha | -52.17 |
Beta | 0.58 |
Volatility | 42.37% |
Current Volume | 593.3k |
Average Volume 20d | 460.7k |
As of February 23, 2025, the stock is trading at USD 20.38 with a total of 593,268 shares traded.
Over the past week, the price has changed by -11.74%, over one month by -15.61%, over three months by -32.03% and over the past year by -37.37%.
Neither. Based on ValueRay Fundamental Analyses, Quanex Building Products is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -16.86 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NX as of February 2025 is 15.94. This means that NX is currently overvalued and has a potential downside of -21.79%.
Quanex Building Products has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy NX.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, NX Quanex Building Products will be worth about 17.8 in February 2026. The stock is currently trading at 20.38. This means that the stock has a potential downside of -12.76%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 36.5 | 79.1% |
Analysts Target Price | 36.3 | 78.3% |
ValueRay Target Price | 17.8 | -12.8% |